MedLife reports 10.70 percent first-half growth: what it means for MedLife stock

Published on 10/05/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MedLife grew pro forma revenue 10.70 percent to RON 1.74 billion in the first half of 2026. For MedLife stock this means RON 20.40 million pro forma net loss.

MedLife, ROMEDLACNOR6, Illustration mit AI erstellt.

MedLife (ROMEDLACNOR6) reported 10.70 percent pro forma revenue growth to RON 1.74 billion in the first half of 2026. In its September 2026 presentation, MedLife also disclosed a pro forma net loss of RON 20.40 million for the period.

What first-half growth means

The operating picture was stronger than the bottom line. Pro forma EBITDA increased 14.50 percent year over year to RON 258.90 million, lifting the pro forma EBITDA margin to 16.40 percent in the first half of 2026.

Under IFRS, revenue rose 10.50 percent to RON 1.74 billion from RON 1.57 billion in the first half of 2025, while operating profit increased 2.30 percent to RON 86.30 million. The comparison shows that MedLife expanded sales and operating earnings, but financial costs and a one-off litigation expense weighed on net results.

Cash flow and segment momentum

MedLife generated RON 141.21 million in operating cash flow in the first half of 2026, up 40.00 percent from RON 100.58 million a year earlier. Net debt reached RON 1.87 billion at June 30, 2026, and the net debt to pro forma EBITDA ratio was 3.85 times.

Corporate revenue increased 16.90 percent to RON 175.64 million, clinic revenue rose 15.10 percent to RON 674.99 million, and laboratory revenue advanced 12.60 percent to RON 194.56 million. Pharmacy revenue grew 33.70 percent to RON 50.46 million, while dentistry revenue declined 3.90 percent to RON 59.59 million, highlighting the uneven contribution across business lines.

Market value and next results

MedLife reported a market capitalization of RON 5.7 billion as of August 31, 2026. The company also reported management share transfers under its remuneration plan on September 22, 2026, according to BVB.

InvestPane lists November 20, 2026 as MedLife's next earnings date. For investors, the central balance is clear: first-half revenue growth and stronger operating cash flow came alongside a RON 20.40 million pro forma net loss and leverage of 3.85 times EBITDA.